Novavax Competitors and Similar CompaniesClear all
Novavax's competitors and similar companies include Proteus Digital Health, Metabolon, PolyPid and Adaptimmune.
 Novavax Novavax is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. |  Proteus Digital Health Proteus Digital Health is a company developing digital products that collect and aggregate various behavioral, physiological and therapeutic metrics. |  Metabolon Global leader in metabolomics for precision medicine, biomarker discovery, and advancing pharma & life sciences research. |  PolyPid PolyPid is a company developing a technology platform that enables a controlled and prolonged release of active pharmaceutical ingredients (API). |  Adaptimmune Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. | |
Founding Date | Founding Date 1987 | Founding Date 2001 | Founding Date 2000 | Founding Date 2008 | Founding Date 2008 |
Type | Type Public | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Gaithersburg, US HQ Jevany, CZ Uppsala, SE Rockville, US | Locations Redwood City, US HQ Hayward, US | Locations Morrisville, US HQ Hallbergmoos, DE München, DE | Locations Petah Tikva, IL HQ Summit, US | Locations Philadelphia, US HQ Milton, GB Milton, GB Stevenage, GB |
Employees | Employees 16845% decrease | Employees 632% increase | Employees 1911% increase | Employees 57 | Employees 4007% decrease |
Valuation ($) | Valuation ($) 1.6 b | Valuation ($) 1.6 b | Valuation ($) N/A | Valuation ($) 23.7 m | Valuation ($) 188.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $1.1b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $178m (FY, 2024) |
Cost of goods | Cost of goods $73m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $70k (FY, 2024) |
Gross profit | Gross profit $1.1b (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $178m (FY, 2024) |
Net income | Net income $440.3m (FY, 2025) | Net income N/A | Net income N/A | Net income ($34.2m) (FY, 2025) | Net income ($70.8m) (FY, 2024) |
Operating ⚠ | |||||
Patent Applications | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A | Patent Applications 49 (FY, 2017) | Patent Applications 69 (FY, 2016) |
Patents Issued | Patents Issued N/A | Patents Issued 600 (May, 2020) | Patents Issued N/A | Patents Issued 104 (FY, 2017) | Patents Issued 173 (FY, 2016) |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 88m (over 7 years ago) | Latest funding round $ 15m (over 9 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised N/A | Total funding raised $ 517m | Total funding raised $ 95.4m | Total funding raised $ 103.8m | Total funding raised $ 107.5m |
For sources of this data, please see the company profile
View Company Profiles
Proteus Digital Health
HQ
Redwood City, US
Employees
63↑ 2% increase
Proteus Digital Health is a company developing digital products that collect and aggregate various behavioral, physiological and therapeutic metrics.
View companyMetabolon
HQ
Morrisville, US
Employees
191↑ 1% increase
Global leader in metabolomics for precision medicine, biomarker discovery, and advancing pharma & life sciences research.
View companyPolyPid
HQ
Petah Tikva, IL
Employees
57
PolyPid is a company developing a technology platform that enables a controlled and prolonged release of active pharmaceutical ingredients (API).
View companyAdaptimmune
HQ
Philadelphia, US
Employees
400↓ 7% decrease
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
View company